Preferred hydroxymethylglutaryl-coenzyme A reductase inhibitors: treatment-modification program and outcomes.
Moisan
J
J
Pharmacoepidemiology Unit, Faculty of Pharmacy, Laval University, Québec City, Québec, Canada. jocelyne.moisan@pha.ulaval.ca
Vaillancourt
R
R
Grégoire
J P
JP
Gaudet
M
M
Côté
I
I
Leach
A
A
D000214:Acyl Coenzyme A / Q000008:administration & dosage* / Q000191:economics; D000924:Anticholesteremic Agents / Q000008:administration & dosage* / Q000191:economics; D002170:Canada; D003362:Cost-Benefit Analysis; D004334:Drug Administration Schedule; D005229:Fatty Acids, Monounsaturated / Q000008:administration & dosage* / Q000191:economics; D000077340:Fluvastatin; D006801:Humans; D006937:Hypercholesterolemia / Q000188:drug therapy* / Q000191:economics; D007211:Indoles / Q000008:administration & dosage* / Q000191:economics; D008499:Medical Records; D008889:Military Personnel; D019821:Simvastatin / Q000008:administration & dosage* / Q000191:economics; D016896:Treatment Outcome
D000214:Acyl Coenzyme A; D000924:Anticholesteremic Agents; D005229:Fatty Acids, Monounsaturated; D007211:Indoles; C008047:3-hydroxy-3-methylglutaryl-coenzyme A; D000077340:Fluvastatin; D019821:Simvastatin